GlassScriptPhysician profile
Awais Malik
NPI 1508025594
$15,749.63
in general payments reported to CMS, 2019-2025
54 companies · $2,811 in 2025
The $2,811 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,251 · 2020: $2,151 · 2021: $2,323 · 2022: $1,903 · 2023: $1,988 · 2024: $2,322 · 2025: $2,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,038 · Education: $83.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,038.24 |
| Education | $83.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,689.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,743.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,653.15 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Abbvie INC. | $1,549.91 | 2021-2025 | |
| Pfizer INC. | $1,090.16 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $935.35 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $840.76 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $722.44 | 2022-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $574.67 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $443.40 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $315.09 | 2019-2023 | Verquvo, Belsomra, Steglujan |
| Abbott Laboratories | $273.69 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $272.29 | 2019-2023 | |
| Amgen INC. | $261.01 | 2020-2025 | Repatha, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $260.61 | 2019-2020 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Awais Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.